Fredun Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Fredun Pharmaceuticals Ltd reported a 32.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 27.3%.
• Its expenses for the quarter were up by 37.4% QoQ and 26.0% YoY.
• The net profit increased 2.9% QoQ and increased 79.7% YoY.
• The earnings per share (EPS) of Fredun Pharmaceuticals Ltd stood at 18.22 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Fredun Pharmaceuticals Ltd is a company operating in the pharmaceutical industry. This sector is known for its focus on the research, development, manufacturing, and marketing of drugs and other healthcare products. While specific details about Fredun Pharmaceuticals Ltd's main products or services are not provided in the data, companies in this industry typically engage in producing generic or branded medications, over-the-counter remedies, and health supplements. Recent developments in the pharmaceutical industry often include advancements in drug formulation, regulatory changes, and shifts in market demand due to health trends and global health challenges. However, without further details, any recent major developments specific to Fredun Pharmaceuticals Ltd remain unspecified.

Revenue

For the quarter ending in Q4FY26, Fredun Pharmaceuticals Ltd reported a total income of ₹213.06 crores. This represents a quarter-over-quarter (QoQ) increase of 32.4% from ₹160.92 crores in Q3FY26, and a year-over-year (YoY) increase of 27.3% from ₹167.41 crores in Q4FY25. The significant growth in revenue indicates a robust performance in the latest quarter relative to previous periods, with both QoQ and YoY metrics showing positive trends. The increase in total income suggests that Fredun Pharmaceuticals Ltd has experienced a substantial increase in sales or other income-generating activities in recent months compared to both the preceding quarter and the same quarter last year.

Profitability

Fredun Pharmaceuticals Ltd recorded a profit before tax (PBT) of ₹11.25 crores in Q4FY26, which is a decrease of 19.6% QoQ from ₹14.00 crores in Q3FY26. However, the PBT showed a 55.0% YoY increase from ₹7.26 crores in Q4FY25. After accounting for tax, the profit after tax (PAT) was ₹10.78 crores, marking a modest QoQ increase of 2.9% from ₹10.48 crores, and a substantial YoY increase of 79.7% from ₹6.00 crores in the previous year. Earnings per share (EPS) for Q4FY26 were ₹18.22, down 17.9% QoQ from ₹22.19, but up 43.4% YoY from ₹12.71. These figures reflect a mixed performance in profitability, with notable improvement in YoY PAT and EPS, despite a decline in QoQ PBT.

Operating Metrics

In Q4FY26, Fredun Pharmaceuticals Ltd reported total expenses of ₹201.81 crores, a 37.4% QoQ increase from ₹146.92 crores in Q3FY26, and a 26.0% YoY increase from ₹160.15 crores in Q4FY25. The tax expense for Q4FY26 was ₹0.47 crores, showing a significant decrease of 86.6% QoQ from ₹3.52 crores, and a 62.7% YoY decrease from ₹1.26 crores. The QoQ decrease in tax expenses coupled with an increase in total expenses suggests changes in cost structures or possible tax efficiencies. The data indicates Fredun Pharmaceuticals Ltd faced higher operational costs in the latest quarter compared to both the previous quarter and the same period last year.